Group sales came in at EUR 13.4B vs. EUR 13.7B last year. EBITDA before special items was EUR 4.45B vs. EUR 4.09B last year. Group EBIT came in at EUR 3.5B vs. EUR 2.3B last year. Net income amounted to EUR 2.76B vs. EUR 1.3B last year. Free cash flow was (EUR 2.3B) vs. (EUR 1.5B) last year. Net financial debt at EUR 32.5B. “We’re pleased with how our businesses started the year and we’re confirming our currency-adjusted outlook for 2026,” CEO Bill Anderson said. Commenting on the company’s strategic priorities, he explained that “we continue to advance our plan and we’re dialed in on delivering our commitments in the current year.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- BridgeBio announces new data of Phase 3 ATTRibute-CM study at Heart Failure 2026
- The Week That Was, The Week Ahead: Macro and Markets, May 10
- Bayer reports REVEAL study met primary endpoints
- Bayer to acquire Perfuse Therapeutics for $300M upfront
- Bayer upgraded to Buy from Neutral at Rothschild & Co Redburn
